On the stock market since 1993, it operates in the world of health and science. It has 275 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 22% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $302.8M in the vault; even if every debt were paid off, $290.6M would remain.
Over the last 12 months, company executives reported 62 buys and 26 sells. Management buying with its own money is usually read as a good sign.
A loss of $38.8M against $213.6M in annual sales. And on top of that, sales fell from the year before.
The stock trades 85% above the average analyst price target.
On our five-subject report card, AMRN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AMRN is a small company that closed last year at a loss. The road back to profit runs through spending discipline.